EGFR and non-small cell lung carcinoma: Therefore, our results suggest a promising use of TrxR1 as a valuable prognostic marker in EGFR wild type, ALK negative advanced NSCLC patients, and the combined detection of TrxR1 and CEA may be able to select poor prognosis patients more accurately.